"Designing Growth Strategies is in our DNA"

Breast Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, and Immunotherapy), By Cancer Type (Hormone Receptor, and HER2+), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2020-2027

Region : Global | Format: PDF | Report ID: FBI100163

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The global breast cancer therapeutics market size was USD 21.58 billion in 2019 and is projected to reach USD 55.27 billion by 2027, exhibiting a CAGR of 13.1% during the forecast period.


The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diagnosed with breast cancer across the globe, the need for accurate and efficient treatment outcomes for the patient remains unparalleled. Furthermore, the strong trend of continuous R&D amongst key market players engaged in breast cancer therapeutics would lead to the launch of breakthrough therapeutics in the coming years. This trend of introducing new and advanced therapies such as targeted therapies and immunotherapies is expected to strongly surge the growth of the global market in developed as well as emerging regions during the forecast period.


COVID-19 Pandemic to Hinder Growth Fueled by Cancellation of Medical Procedures


In terms of the pharmaceutical industry, the COVID-19 pandemic is expected to have multiple positive and negative impacts. Several governments implemented strict nationwide lockdowns during the initial stages of the pandemic to limit the coronavirus spread. This led the healthcare industry to suffer from some critical negative impacts as the flow of patients to treatment settings reduced substantially.


Furthermore, the impact grew stronger as many regulations stated the postponement or cancellation of non-essential or elective medical procedures. The COVID-19 pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients. At the same time, there was some impact, such as restricted growth, as in certain cases, the procedures were postponed to a later date. Hence, the global market has showcased a restricted or limited growth due to the COVID-19 pandemic.


LATEST TRENDS


Request a Free sample to learn more about this report.


Increasing R&D Initiatives to Create Sophisticated Breast Cancer Therapeutics is a Vital Trend


One of the most prevalent trends in the global market is the ongoing R&D initiatives for the development and the marketing of efficient drugs for breast cancer treatment. As the number of patients suffering from breast cancer continues to increase across the globe, the importance and the critical need for the development of advanced therapeutics for better outcomes remains unparalleled.



  • For instance, Sanofi, one of the key players in the breast cancer therapeutics industry, has been conducting R&D initiatives to develop novel oral treatments for metastatic breast cancer.

  • Additionally, AstraZeneca has been conducting R&D activities for the development of therapeutics to treat estrogen receptor-positive breast cancer.


Such trends are expected to significantly boost the global breast cancer therapeutics market growth in the forecast period as the development of new therapeutics is expected to lead to new product launches. This is further set to result in greater sales of breast cancer drugs and the inclusion of new patients in the treatment process, as more types of breast cancers are anticipated to be treated through these new drugs.


DRIVING FACTORS


Increasing Prevalence of Breast Cancer to Drive Growth


One of the foremost drivers influencing the growth of the global market is the increased prevalence of breast cancer across the world, which is expected to result in a large patient population demanding accurate and efficient treatment options. Breast cancer is one of the most prevalent forms of cancer worldwide and improved diagnostics are further expected to result in a greater number of patients being diagnosed.



  • For instance, according to the statistics published by the World Cancer Research Fund (WCRF), in 2018, 2,088,849 new cases of breast cancer were diagnosed across the world. Hence, the existence of a sizable patient population, which is projected to grow in the forecast period, is likely to surge the market growth.


Furthermore, the increasing demand for preventive care and early treatment has led many individuals to undergo cancer screening tests, which would also strongly drive the number of patients demanding treatment in the forecast period. Besides, the increasing patient awareness due to such alarming statistics is anticipated to further drive the market growth. Hence, the rising prevalence of breast cancer is projected to boost market growth in the forecast period.


Launch of Technologically Advanced Therapeutics to Aid Growth


One of the critical factors that are expected to strongly propel the market growth in the forthcoming years is new product launches for the treatment of breast cancer by key players. These product launches are projected to positively impact the market as they are technologically advanced and may often result in better treatment outcomes for patients.


Furthermore, some of the new product launches are specifically aimed at the treatment of breast cancer that was previously untreatable, or the earlier treatments were not successful in terms of improved outcomes for patients.



  • For instance, the U.S. FDA granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to the other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.


Therefore, these factors are projected to positively impact the market during the forecast period.


RESTRAINING FACTORS


Adverse Effects of Therapeutics May Hinder Growth


Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth in the near future. For instance, according to the American Cancer Society (ACS), targeted therapies have several side effects, namely, skin problems, gastrointestinal problems such as diarrhea, and high blood pressure. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. For instance, severe side effects of targeted therapy include rashes in several parts of the body and also the occurrence of blisters. Similarly, immunotherapy has numerous side effects, such as fatigue and nausea. These adverse reactions are expected to limit market growth in the forecast period.


SEGMENTATION


By Therapy Analysis


To know how our report can help streamline your business, Speak to Analyst


Targeted Therapy Segment to Grow at a Faster Pace during 2020-2027


On the basis of therapy, this market is categorized into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. The targeted therapy segment can be further divided into abemaciclib, ado-trastuzumab emtansine, everolimus, trastuzumab, ribociclib, palbociclib, pertuzumab, olaparib, and others. The targeted therapy segment held a dominant share of the market in 2019. The dominance is owing to the greater adoption of this therapy in developed and emerging countries. Also, a large number of new product launches and the presence of an overwhelming number of drugs under this segment would accelerate growth. Some of the important targeted therapy products include Kadcyla, Afinitor/Afinitor Disperz/Zortress, and Lynparza.


The hormonal therapy segment can be further segmented into selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators (ERDs). The hormonal therapy segment is anticipated to register a lower market share in the forecast period. This is primarily attributable to the increasing availability of generic equivalents of hormonal therapy drugs.


Similarly, the chemotherapy segment is anticipated to register a lower growth rate and share due to the increasing influx of generic equivalents. The immunotherapy segment is set to register a higher growth rate due to their recent regulatory approvals by the U.S. FDA.


By Cancer Type Analysis


Hormone Receptor Segment Accounted for the Highest Share in 2019


Based on the cancer type, the market is segmented into the hormone receptor and HER2+. The hormone receptor segment is likely to dominate the market during the forecast period because of the rising volume of breast cancer patients belonging to this type of cancer. Hence, this segment would maintain its dominance in the global market.


The HER2+ segment accounted for a lower share of the global market but is expected to register a comparatively higher CAGR due to the recent launches of therapeutics for the treatment of this type of breast cancer.


By Distribution Channel Analysis


Hospital Pharmacies Dominated in 2019 Stoked by Need to Administer Various Therapies


On the basis of the distribution channel, the market is segregated into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is projected to account for a higher share of the global market because of the dependency of patients on these pharmacies for the administration of therapies, such as chemotherapy.


The retail pharmacies segment would account for the second-largest share in the forecast period since a large number of patients depend on them for the filling up of oral prescription drugs. The online pharmacies segment is expected to showcase the highest CAGR as the increasing number of patients have shifted to these pharmacies as a means of acquiring therapeutics due to their greater ease in terms of usage.


REGIONAL INSIGHTS


North America Breast Cancer Therapeutics Market Size, 2019 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


In terms of region, the global market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market size in North America stood at USD 10.34 billion in 2019. The region is projected to be the key market in the forecast period. This growth is attributable to the presence of prominent companies in the region, which, in turn, would lead to the launch of new therapeutics in the region. Other reasons include the strong prevalence of breast cancer, the increasing number of breast cancer therapeutics R&D clinical trials, and the increased awareness and adoption of advanced therapeutics.



  • For instance, according to the American Cancer Society, in 2020, it was estimated that in the United States, approximately 276,480 new cases of invasive breast cancer would be diagnosed in women.


Europe is projected to be the second-most dominant region in the forecast period owing to the increasing incidence of breast cancer in the region, coupled with greater adoption of advanced therapeutics. For instance, according to the statistics released by the Joint Research Center (JRC) of the European Union, female breast cancer is the most common cancer diagnosed in Europe. In 2020, over 355,000 women in the EU-27 were estimated to be diagnosed with breast cancer.


The Asia Pacific market is anticipated to register the highest growth backed by the increased demand for sophisticated and advanced drugs, increasing patient population, and the significant surge in healthcare expenditure. For instance, in April 2020, F. Hoffmann-La Roche Ltd announced the launch of the immunotherapy drug atezolizumab for the treatment of metastatic triple-negative breast cancer (TNBC) in India.


The emerging markets of Latin America and the Middle East & Africa accounted for a comparatively lower share in 2019. But, they are anticipated to experience strong growth in the forecast period due to the increased presence of prominent companies in the regions, rising healthcare expenditure, surging patient population, and high demand for advanced therapeutics.


KEY INDUSTRY PLAYERS


Strong Product Portfolio of Pfizer, Inc. and Baxter Has Led These Companies to Market Dominance


In terms of the competitive landscape, some of the key characteristics of the global market include the dominance of a few key players engaged in the sales of oncology therapeutics. Some of them are Genentech (F. Hoffmann-La Roche Ltd), AstraZeneca, Pfizer Inc., and Novartis AG. Collectively, these companies account for the dominant share of the market due to their strong and robust product portfolios of drugs for breast cancer treatment.


Furthermore, these companies are engaged in cutting edge R&D for the development of pharmaceuticals for the treatment of breast cancer. For instance, Genentech (F. Hoffmann-La Roche Ltd) has a wide range of strong breast cancer therapies in its product portfolio, including Kadcyla, Xeloda, Perjeta, and Herceptin.


Other important players in the breast cancer therapeutics industry include Sanofi, Bristol Myers Squibb (Celgene Corporation), Eli Lilly and Company, and Eisai Co. Ltd. Their various strategic executions are expected to contribute to their efforts in the expansion of their market revenue in the forecast period.


LIST OF KEY COMPANIES PROFILED:



  • Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)

  • Eli Lilly and Company (Indianapolis, U.S.)

  • Novartis AG (Basel, Switzerland)

  • AstraZeneca (Cambridge, U.K.)

  • Pfizer Inc. (New York City, U.S.)

  • Sanofi (Paris, France)

  • Eisai Co. Ltd. (Tokyo, Japan)

  • Kyowa Kirin (Tokyo, Japan)

  • Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)

  • Merck & Co., Inc. (Kenilworth, U.S.)

  • Other Players


KEY INDUSTRY DEVELOPMENTS:



  • September 2020 – Natco Pharma announced that its marketing partner, Lupin, launched Lapatinib Tablets, 250 mg, in the U.S. after Natco received the final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the first ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification.

  • June 2020 – The U.S. FDA announced the approval of Phesgo—a combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body and for treatment of adult patients with early HER2-positive breast cancer. The patients undergoing this therapy should be selected based on an FDA-approved companion diagnostic test.


REPORT COVERAGE


An Infographic Representation of Breast Cancer Therapeutics Market

To get information on various segments, share your queries with us



The market research report provides a detailed analysis of the market. It focuses on key aspects such as key industry developments - mergers, acquisitions, and partnerships, regulatory scenarios by key regions, the prevalence of breast cancer by key countries, and an overview of current advances in R&D for therapeutics of breast cancer. Besides this, it offers insights into the breast cancer therapeutics market trends and highlights key industry dynamics. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the global market over recent years.


Report Scope & Segmentation


















































  ATTRIBUTE



   DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD billion)



Segmentation



  Therapy, Cancer Type, Distribution Channel, and Geography



By Therapy


 




  • Targeted Therapy


    • Abemaciclib

    • Ado-Trastuzumab Emtansine

    • Everolimus

    • Trastuzumab

    • Ribociclib

    • Palbociclib

    • Pertuzumab

    • Olaparib

    • Others




  • Hormonal Therapy

    • Selective Estrogen Receptor Modulators (SERMs)

    • Aromatase Inhibitors

    • Estrogen Receptor Downregulators (ERDs)



  • Chemotherapy

  • Immunotherapy



By Cancer Type


 




  • Hormone Receptor

  • HER2+



By Distribution Channel


 




  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others



By Geography


 




  • North America

    • By Therapy

    • By Cancer Type

    • By Distribution Channel

    • By Country

      • U.S.  (By Therapy)

      • Canada  (By Therapy)





  • Europe

    • By Therapy

    • By Cancer Type

    • By Distribution Channel

    • By Country/ Sub-Region

      • UK  (By Therapy)

      • Germany  (By Therapy)

      • France  (By Therapy)

      • Italy  (By Therapy)

      • Spain  (By Therapy)

      • Scandinavia  (By Therapy)

      • Rest of Europe  (By Therapy)





  • Asia Pacific

    • By Therapy

    • By Cancer Type

    • By Distribution Channel

    • By Country/ Sub-Region

      • Japan  (By Therapy)

      • China  (By Therapy)

      • India  (By Therapy)

      • Australia  (By Therapy)

      • South East Asia  (By Therapy)

      • Rest of Asia Pacific  (By Therapy)





  • Latin America

    • By Therapy

    • By Cancer Type

    • By Distribution Channel

    • By Country/ Sub-Region

      • Brazil  (By Therapy)

      • Mexico  (By Therapy)

      • Rest of South America  (By Therapy)





  • Middle East & Africa

    • By Therapy

    • By Cancer Type

    • By Distribution Channel

    • By Country/ Sub-Region

      • South Africa  (By Therapy)

      • GCC Countries  By Therapy

      • Rest of Middle East & Africa  (By Therapy)







Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 21.58 billion in 2019 and is projected to reach USD 55.27 billion by 2027.

In 2019, the North America market value stood at USD 10.34 billion.

Registering a CAGR of 13.1%, the market will exhibit steady growth in the forecast period (2020-2027).

The targeted therapy segment is expected to lead the market during the forecast period.

The increasing prevalence of breast cancer, strong demand for effective therapeutics from a substantial patient population base, and new product launches are the key factors driving the growth of the market.

Genentech (F. Hoffmann-La Roche Ltd), AstraZeneca, Pfizer Inc., and Novartis AG are some of the major players in the global market.

North America dominated the market in terms of share in 2019.

New product launches by key companies and the strong prevalence of breast cancer necessitating effective therapeutics are expected to drive the adoption of this therapeutics.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Breast Cancer Therapeutics Market Size, Share and Global Industry Trend Forecast till 2026
  • Jan, 2021
  • 2019
  • 2016-2018
  • 175

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X